Stray Dog

Moat

Last reviewed 29 Oct 2026

Strong on its subscribers' health data and its founder, with more of its own factories and labs than most assume

Read more

The pressure is on margins: its fastest-growing drug is not its own, so Hims does not set the price.

Proprietary data flywheel · Strong. Every consultation, test and treatment adds to a health record a newcomer cannot rebuild overnight. Unproven so far: Hims has never said how many people buy a second product.

Regulation & licences · Neutral. Weight-loss rules have been more threat than shield, but making its own drugs under licence turns that risk into something it controls. Treatments that need a video visit with a doctor and regular blood tests, like testosterone, shut out small telehealth brands.

Physical assets & network · Strong. A drug-making campus of over 300,000 square feet in Ohio, drug compounding in California and its own diagnostics lab: not the asset-light platform it is often taken for.

Trust & brand · Neutral. Well known with consumers, but after the weight-loss drug dispute, trust takes time to rebuild, and the FTC's main charge is about privacy: health information shared with advertising platforms.

Owner-operator · Strong. Co-founder Andrew Dudum is still CEO and keeps the high-vote shares, so other owners have little say, a trade-off many investors see as a serious risk. His bets are large, with no track record at this scale.

Leadership

Last reviewed 29 Oct 2026

Andrew Dudum

Andrew Dudum

Co-founder, CEO and chairman

10 years at the helm
Owns7.1%
Votes87.7%

Founder and control · Strong. 175 votes a share: about 88% of all votes.

Skin in the game · Neutral. Owns about 7%. Sold about $200 million in 2024–25, bought none.

Track record · Neutral. Opened category after category, but made 'a significant mistake' in weight loss.

Pay and alignment · Strong. Over 90% of his pay is stock, tied to 2027 targets.

Bench and succession · Weak. Strong new hires, but control rests with one man.

Briefs

Kentucky rejects federal peptide easing, a risk for HIMS

Hims & Hers: Hers UK launches Care+; peptides under scrutiny

Hims launches Peptides+ with 5 compounded products

Noom launches OpenRx peptides brand, rival to HIMS

Hims & Hers: FTC suit widens to seven states